Patents by Inventor Milana Maletic

Milana Maletic has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Preparation and use of 7a-heterocycle substituted-6,6-difluoro bicyclic himbacine derivatives as PAR-1 receptor antagonists
    Patent number: 10322140
    Abstract: The present invention relates to bicyclic himbacine derivatives of the formula or a pharmaceutically acceptable salt thereof wherein: R1 is W is and the remaining variables are described herein. The compounds of the invention are effective inhibitors of the PAR-1 receptor. The inventive compounds may be used for the treatment or prophylaxis of disease states such as ASC, secondary prevention of myocardial infarction or stroke, or PAD.
    Type: Grant
    Filed: September 26, 2017
    Date of Patent: June 18, 2019
    Inventors: Zhiqiang Yang, Guizhen Dong, Milana Maletic
  • Imidazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
    Patent number: 9981969
    Abstract: The present invention relates to Imidazole Derivatives of Formula (I), and pharmaceutically acceptable salts thereof, wherein A, B, Y, R1 and R2 are as defined herein. The present invention also relates to compositions comprising at least one Imidazole Derivative, and methods of using the Imidazole Derivatives for inhibiting CYP450 3A. Inhibition of CYP450 3A can be used to improve the pharmacokinetics of a drug that is metabolized by CYP450 3A4.
    Type: Grant
    Filed: June 2, 2014
    Date of Patent: May 29, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Craig A. Coburn, Milana Maletic, Yunfu Luo, Zhiqi Qi, Chunsing Li, Tingting Yu, Richard Soll
  • PREPARATION AND USE OF 7A-HETEROCYCLE SUBSTITUTED- 6,6-DIFLUORO BICYCLIC HIMBACINE DERIVATIVES AS PAR-1 RECEPTOR ANTAGONISTS
    Publication number: 20180015106
    Abstract: The present invention relates to bicyclic himbacine derivatives of the formula or a pharmaceutically acceptable salt thereof wherein: R1 is W is and the remaining variables are described herein. The compounds of the invention are effective inhibitors of the PAR-1 receptor. The inventive compounds may be used for the treatment or prophylaxis of disease states such as ASC, secondary prevention of myocardial infarction or stroke, or PAD.
    Type: Application
    Filed: September 26, 2017
    Publication date: January 18, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Zhiqiang Yang, Guizhen Dong, Milana Maletic
  • Preparation and use of 3-pyridyl substituted-6,6-difluoro bicyclic himbacine derivatives as par-1 receptor antagonists
    Patent number: 9808473
    Abstract: The present invention relates to bicyclic himbacine derivatives of the formula or a pharmaceutically acceptable salt thereof wherein: R1 is halo; —CN; alkyl; cycloalkyl; alkoxy; phenyl, which is optionally substituted one or twice independently by alkyl, halo, or —CN; or a thiophene ring, which is optionally substituted once or twice independently by alkyl. The compounds of the invention are effective inhibitors of the PAR-1 receptor. The inventive compounds may be used for the treatment or prophylaxis of disease states such as ASC, secondary prevention of myocardial infarction or stroke, or PAD.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: November 7, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: James Francis Dropinski, Milana Maletic, Jae-Hun Kim, Deyou Sha
  • Preparation and Use of Cyclic Sulfonamide Derivatives as PAR-1 Receptor Antagonists
    Publication number: 20170240539
    Abstract: The present invention relates to cyclic sulfonamide derivatives of Formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 9, 2015
    Publication date: August 24, 2017
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Andrew W. Stamford, Zhi-Qiang Yang, Milana Maletic, Senlin Cai, Xiaobang Duan, Jianhua Cao
  • Preparation and use of 7a-amide substituted- 6,6-difluoro bicyclic himbacine derivatives as PAR-1 receptor antagonists
    Patent number: 9701669
    Abstract: The present invention relates to bicyclic himbacine derivatives of the formula or a pharmaceutically acceptable salt thereof wherein: R1 is —[C(Ra)(Rb)]x—[C(Rb)(Rb)]y—C(O)NH2, or —N(H)—[(CH2)]z—C(O)—NH2, W is and the remaining variables are described herein. The compounds of the invention are effective inhibitors of the PAR-1 receptor. The inventive compounds may be used for the treatment or prophylaxis of disease states such as ASC, secondary prevention of myocardial infarction or stroke, or PAD.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: July 11, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Zhiqiang Yang, Fengqi Zhang, Guizhen Dong, Sandra Lee Knowles, Milana Maletic
  • Sulfonamide derivatives and methods of use thereof for improving the pharmacokinetics of a drug
    Patent number: 9556202
    Abstract: The present invention relates to Sulfonamide Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, W, X, R1, R2, R3, R4 and R5 are as defined herein. The present invention also relates to compositions comprising at least one Sulfonamide Derivative, and methods of using the Sulfonamide Derivatives for improving the pharmacokinetics of a drug.
    Type: Grant
    Filed: June 25, 2013
    Date of Patent: January 31, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Craig A. Coburn, Milana Maletic, Richard Soll, Chunsing Li, Yunfu Luo, Zhiqi Qi
  • PREPARATION AND USE OF 3-PYRIDYL SUBSTITUTED- 6,6-DIFLUORO BICYCLIC HIMBACINE DERIVATIVES AS PAR-1 RECEPTOR ANTAGONISTS
    Publication number: 20160200713
    Abstract: The present invention relates to bicyclic himbacine derivatives of the formula or a pharmaceutically acceptable salt thereof wherein: R1 is halo; —CN; alkyl; cycloalkyl; alkoxy; phenyl, which is optionally substituted one or twice independently by alkyl, halo, or —CN; or a thiophene ring, which is optionally substituted once or twice independently by alkyl. The compounds of the invention are effective inhibitors of the PAR-1 receptor. The inventive compounds may be used for the treatment or prophylaxis of disease states such as ASC, secondary prevention of myocardial infarction or stroke, or PAD.
    Type: Application
    Filed: August 18, 2014
    Publication date: July 14, 2016
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: James Francis Dropinski, Milana Maletic, Jae-hun Kim, Deyou Sha
  • PREPARATION AND USE OF 7A-HETEROCYCLE SUBSTITUTED- 6,6-DIFLUORO BICYCLIC HIMBACINE DERIVATIVES AS PAR-1 RECEPTOR ANTAGONISTS
    Publication number: 20160200715
    Abstract: The present invention relates to bicyclic himbacine derivatives of the formula or a pharmaceutically acceptable salt thereof wherein: R1 is W is and the remaining variables are described herein. The compounds of the invention are effective inhibitors of the PAR-1 receptor. The inventive compounds may be used for the treatment or prophylaxis of disease states such as ASC, secondary prevention of myocardial infarction or stroke, or PAD.
    Type: Application
    Filed: August 18, 2014
    Publication date: July 14, 2016
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Zhiqiang Yang, Guizhen Dong, Milana Maletic
  • PREPARATION AND USE OF 7A-AMIDE SUBSTITUTED- 6,6-DIFLUORO BICYCLIC HIMBACINE DERIVATIVES AS PAR-1 RECEPTOR ANTAGONISTS
    Publication number: 20160185764
    Abstract: The present invention relates to bicyclic himbacine derivatives of the formula or a pharmaceutically acceptable salt thereof wherein: R1 is —[C(Ra)(Rb)]x—[C(Rb)(Rb)]y—C(O)NH2, or —N(H)—[(CH2)]z—C(O)—NH2, W is and the remaining variables are described herein. The compounds of the invention are effective inhibitors of the PAR-1 receptor. The inventive compounds may be used for the treatment or prophylaxis of disease states such as ASC, secondary prevention of myocardial infarction or stroke, or PAD.
    Type: Application
    Filed: August 18, 2014
    Publication date: June 30, 2016
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Zhiqiang Yang, Fengqi Zhang, Guizhen Dong, Sandra Lee Knowles, Milana Maletic
  • IMIDAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG
    Publication number: 20160108048
    Abstract: The present invention relates to Imidazole Derivatives of Formula (I), and pharmaceutically acceptable salts thereof, wherein A, B, Y, R1 and R2 are as defined herein. The present invention also relates to compositions comprising at least one Imidazole Derivative, and methods of using the Imidazole Derivatives for inhibiting CYP450 3A. Inhibition of CYP450 3A can be used to improve the pharmacokinetics of a drug that is metabolized by CYP450 3A4.
    Type: Application
    Filed: June 2, 2014
    Publication date: April 21, 2016
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Craig A. Coburn, Milana Maletic, Yunfu Luo, Zhiqi Qi, Chunsing Li, Tingting Yu, Richard Soll
  • SULFONAMIDE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG
    Publication number: 20150197531
    Abstract: The present invention relates to Sulfonamide Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, W, X, R1, R2, R3, R4 and R5 are as defined herein. The present invention also relates to compositions comprising at least one Sulfonamide Derivative, and methods of using the Sulfonamide Derivatives for improving the pharmacokinetics of a drug.
    Type: Application
    Filed: June 25, 2013
    Publication date: July 16, 2015
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Craig A. Coburn, Milana Maletic, Richard Soll, Chunsing Li, Yunfu Luo, Zhiqi Qi
  • Substituted piperidinyl compounds useful as GPR119 agonists
    Patent number: 9018200
    Abstract: Substituted piperidinyl compounds of the formula (I): are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. Pharmaceutically acceptable salts are included as well. The compounds are useful as agonists of the g-protein coupled receptor GPR-119.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: April 28, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Milana Maletic, Harold B. Wood, Wanying Sun
  • Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
    Patent number: 8957062
    Abstract: Substituted cyclopropyl compounds of the formula I: and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR-119. Pharmaceutical compositions and methods of treatment are also included.
    Type: Grant
    Filed: April 5, 2012
    Date of Patent: February 17, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Scott Edmondson, Zhiqiang Guo, Harold B. Wood, Andrew W. Stamford, Michael W. Miller, Duane E. DeMong, Gregori J. Morriello, Rajan Anand, Vincent J. Colandrea, Megan Macala, Milana Maletic, Cheng Zhu, Yuping Zhu, Wanying Sun, Kake Zhao, Yong Huang, Joel M. Harris, Lehua Chang, Nam Fung Kar, Zhiyong Hu, Liping Wang, Bowei Wang, Ping Liu, Jason W. Szewczyk, William B. Geiss
  • SUBSTITUTED PIPERIDINYL COMPOUNDS USEFUL AS GPR119 AGONISTS
    Publication number: 20140296202
    Abstract: Substituted piperidinyl compounds of the formula (I): are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. Pharmaceutically acceptable salts are included as well. The compounds are useful as agonists of the g-protein coupled receptor GPR-119.
    Type: Application
    Filed: October 18, 2012
    Publication date: October 2, 2014
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Milana Maletic, Harold B. Wood, Wanying Sun
  • SUBSTITUTED CYCLOPROPLY COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT
    Publication number: 20140057893
    Abstract: Substituted cyclopropyl compounds of the formula I: and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR-119.
    Type: Application
    Filed: April 5, 2012
    Publication date: February 27, 2014
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Scott Edmondson, Zhiqiang Guo, Harold B. Wood, Andrew W. Stamford, Michael W. Miller, Duane E. DeMong, Gregori J. Morriello, Rajan Anand, Vincent J. Colandrea, Megan Macala, Milana Maletic, Cheng Zhu, Yuping Zhu, Wanying Sun, Kake Zhao, Yong Huang, Joel M. Harris, Lehua Chang, Nam Fung Kar, Zhiyong Hu, Liping Wang, Bowei Wang, Ping Liu, Jason W. Szewczyk, William B. Geiss
  • SULFONAMIDE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG
    Publication number: 20140005103
    Abstract: The present invention relates to Sulfonamide Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, W, X, R1, R2, R3, R4 and R5 are as defined herein. The present invention also relates to compositions comprising at least one Sulfonamide Derivative, and methods of using the Sulfonamide Derivatives for improving the pharmacokinetics of a drug.
    Type: Application
    Filed: June 25, 2013
    Publication date: January 2, 2014
    Inventors: Craig A. Coburn, Milana Maletic, Richard Soll, Chunsing Li, Yunfu Luo, Zhiqi Qi
  • Sulfonyl compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
    Patent number: 7915252
    Abstract: Sulfonyl derivatives of structural formula I are selective inhibitors of the 11?-hydroxysteroid dehydrogenase-1. The compounds are useful for the treatment of diabetes, such as noninsulin-dependent diabetes (NIDDM), hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Metabolic Syndrome or Syndrome X, and other symptoms associated with NIDDM.
    Type: Grant
    Filed: August 3, 2005
    Date of Patent: March 29, 2011
    Assignee: Merck Sharp & Dohme
    Inventors: Sherman T. Waddell, James M. Balkovec, Gina M. Santorelli, Aaron H. Leeman, Milana Maletic, Xin Gu
  • 11-?-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
    Patent number: 7329683
    Abstract: Compounds having Formula (I), including pharmaceutically acceptable salts and prodrugs thereof: are selective inhibitors of the 11?-HSD1 enzyme. They inhibit the 11?-HSD1-mediated conversion of cortisone and other 11-keto-glucocorticoids to cortisol and other 11?-hydroxy-glucocorticoids. The 11?-HSD1 inhibitors therefore decrease the amount of cortisol in target tissues, thereby modulating the effects of cortisol.
    Type: Grant
    Filed: January 28, 2003
    Date of Patent: February 12, 2008
    Assignee: Merck & Co., Inc.
    Inventors: James M. Balkovec, Rolf Thieringer, Steven S. Mundt, Anne Hermanowski-Vosatka, Donald W. Graham, Gool F. Patel, Susan D. Aster, Sherman T. Waddell, Steven H. Olson, Milana Maletic
  • Triazole derivatives as inhibitors of 11-beta hydroxysteroid dehydrogenase-1
    Publication number: 20060258695
    Abstract: Triazole derivatives of structural formula I are selective inhibitors of the 11?-hydroxysteroid dehydrogenase-1. The compounds are useful for the treatment of diabetes, such as noninsulin-dependent diabetes (NIDDM), hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Metabolic Syndrome, and other symptoms associated with NIDDM.
    Type: Application
    Filed: May 26, 2004
    Publication date: November 16, 2006
    Inventors: Sherman Waddell, Gina Santorelli, Milana Maletic, Aaron Leeman, Xin Gu, Donald Graham, James Balkovec, Susan Aster